Pfizer’s Five-Year Return Falls Short of S&P 500 Even After Dividends

For many investors, Pfizer (PFE) is viewed as a classic yield play in the pharmaceutical sector, with stable payouts offering income even in periods of share price volatility. As of October 19, 2026, Pfizer’s dividend yield stood at 5.8%, according to Trefis. However, a look at total return figures over the past five years highlights the company’s significant underperformance against the broader market.

Dividend Power Not Enough

Between October 11, 2021, and October 19, 2026, Pfizer’s share price fell 30.0%. Over that same period, the S&P 500 index rose 76.3%, putting Pfizer 106.3 percentage points behind the market on price return alone. Investors focused solely on price would have seen continued losses while the broad market gained.

Including reinvested dividends, Pfizer’s five-year total return improved to a loss of 8.8%, according to Trefis. Dividends added 21.2 percentage points to Pfizer’s return, showing the value of payouts amid share price declines, but not enough to offset the drop. By comparison, the S&P 500’s total return, with dividends, reached 88.1%. This leaves Pfizer 96.9 percentage points behind when accounting for all income.

Pfizer’s dividend payouts added nearly twice the 11.7 percentage points contributed by S&P 500 dividends over the period. Nonetheless, the scale of the share price decline meant that dividends closed less than a tenth of the overall performance gap.

Recent Gains Offer Relief, But Lag Persists

In the most recent year, Pfizer’s returns have improved. Over the past 12 months, the share price rose 21.5%, and the total return with dividends reached 30.0%, compared to the S&P 500’s 17.0% including dividends. In this period, dividends accounted for 8.5 percentage points of Pfizer’s return, compared with about 1 point for the S&P 500.

Year-to-date in 2026 (through mid-October), Pfizer gained 27.2%, outpacing the S&P 500 (+13.4%) and the Health Care Select Sector SPDR ETF (XLV, +17.2%), as reported by Trefis. For income-seeking investors, this recent turnaround provides some relief, though it does not compensate for the longer-term underperformance highlighted in the five-year measures.

Dividend Sustainability and Revenue Base

Pfizer’s dividend outlook depends directly on the company’s business performance. During the August 2026 earnings call, management reaffirmed its commitment to maintaining and growing the dividend. In fiscal 2025, 97.8% of Pfizer’s revenue was generated by its biopharma segment, driven by products like Eliquis and Padcev, according to Trefis.

While dividend payouts softened the loss from share price declines over five years, they did not generate a positive total return over a period when broad market equities performed strongly. For shareowners with a significant allocation to Pfizer, the discrepancy between price movements and dividend income has shaped the return profile of the stock.

Earnings due around November 3

Pfizer’s next earnings report is expected on or around November 3, 2026. The market will be watching for updates on earnings, dividend intentions, and developments within the biopharma business, which accounts for the bulk of Pfizer’s revenue.

Pfizer’s performance over the past five years demonstrates that elevated dividend yields can only partially cushion against periods of sustained share price decline when compared to benchmarks such as the S&P 500. Even with recent gains, the long-term gap remains substantial.